Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.42 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.30 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
| ▸ | CCR8 | P51685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24759813 | 1.00 | MAPKAPK2 (0.42) | MAPKAPK2MAPKAPK5AAK1TGFBR1MAP4K4 | |
| SCHEMBL24461546 | 0.76 | CCR1 (0.52) | MAPKAPK2MAPKAPK5AAK1CCR1CCR5 | |
| SCHEMBL24759414 | 0.75 | MAPKAPK2 (0.38) | MAPKAPK2MAPKAPK5 | |
| SCHEMBL26323494 | 0.74 | — | — | |
| SCHEMBL30514523 | 0.72 | MAPKAPK2 (0.54) | MAPKAPK2MAPKAPK5TGFBR1 | |
| SCHEMBL28917928 | 0.72 | MAPKAPK2 (0.54) | MAPKAPK2MAPKAPK5TGFBR1 | |
| SCHEMBL25604929 | 0.71 | MAPKAPK5 (0.67) | MAPKAPK2MAPKAPK5TGFBR1 | |
| SCHEMBL31305797 | 0.70 | KDM4E (0.43) | MAPKAPK2MAPKAPK5 | |
| SCHEMBL31305799 | 0.70 | MAPKAPK2 (0.40) | MAPKAPK2MAPKAPK5 | |
| SCHEMBL29696893 | 0.70 | MAPKAPK5 (0.65) | MAPKAPK2MAPKAPK5TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | XINTHERA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545662-B2 | MK2 inhibitors and uses thereof | NR3C2, NR2C2, AGTR2 | MAPKAPK2 71/4885MAPKAPK5 679/4885AAK1 1310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.